CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

about

HIV protease inhibitors: a review of molecular selectivity and toxicity

P2860

Q28082749-B77F8ECD-EF22-4E31-BDDD-D792F428603E

P2860

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

Item

http://www.wikidata.org/entity/Q41665599

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

@en

type

Item

label

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

@en

prefLabel

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

@en

P1476

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

@en

P2093

Alfonso Domínguez-Gil Hurlé

http://www.w3.org/2001/XMLSchema#string

Alicia Iglesias Gómez

http://www.w3.org/2001/XMLSchema#string

Elena López Aspiroz

http://www.w3.org/2001/XMLSchema#string

María Paz Valverde Merino

http://www.w3.org/2001/XMLSchema#string

Salvador Enrique Cabrera Figueroa

http://www.w3.org/2001/XMLSchema#string

P2860

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity.

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Lopinavir exposure with an increased dose during pregnancy.

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

P304

61-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40261-014-0245-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25391550

http://www.w3.org/2001/XMLSchema#string

P921

7bèla

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

about

P2860

P2860

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921